Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

atugen AG Discovers Novel Cancer Target

21.01.2003


atugen AG, a private company focused on the elucidation of disease pathways, today announced the identification of a novel cancer target that appears to play an important role in tumor growth and metastasis. atugen’s research group has demonstrated that inhibition of the novel target, Atu027, which has homology to protein kinases, results in blockage of tumor growth of human prostate carcinoma cells in orthotopic mouse models. atugen has demonstrated that human prostate tumor cells engineered to express siRNA molecules against the kinase shows significant reduction or even complete lack of secondary tumors indicating a role of the kinase in tumor progression and metastasis.



The novel target, Atu027, is the result of the company’s internal research program on the phosphatidylinositol 3-OH kinase (PI 3-K) pathway. The approach was presented at the Cold Spring Harbor Laboratory’s Tumor Suppressor August 2002 Meeting in Cold Spring Harbor, NY. PI 3-K is a central signal transduction molecule controlling a wide range of cellular responses including contributing to increased malignant behavior of cancer cells.

The identification and functional validation of the kinase as PI 3-K downstream effector molecule underscores the strength of the atugen approach to find novel targets. The use of the company’s proprietary mRNA knockdown technologies (GeneBlocs® antisense molecules, improved synthetic siRNA, vector expression systems for siRNA, ribozymes and superior transfection reagents) together with atugen’s expertise in gene function elucidation has to date resulted in 19 functionally validated cancer targets that act in the PI 3-K pathway.


“We are in the process of out-licensing this novel kinase target to partners,” said Dr. Klaus Giese, atugen’s Chief Scientific Officer and Vice President of Research. “The breakthrough in this complex pathway endorses our approach, which aims at providing our partners and in-house projects with the best targets for therapeutic intervention within a given disease cascade. We have already started to dissect a complementary pathway, the TGF-beta/Smad pathway.”

Caroline Stupnicka | alfa
Further information:
http://www.atugen.de

More articles from Health and Medicine:

nachricht Diabetes mellitus: A risk factor for early colorectal cancer
27.05.2020 | Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg

nachricht Ultra-thin fibres designed to protect nerves after brain surgery
27.05.2020 | Martin-Luther-Universität Halle-Wittenberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Small Protein, Big Impact

In meningococci, the RNA-binding protein ProQ plays a major role. Together with RNA molecules, it regulates processes that are important for pathogenic properties of the bacteria.

Meningococci are bacteria that can cause life-threatening meningitis and sepsis. These pathogens use a small protein with a large impact: The RNA-binding...

Im Focus: K-State study reveals asymmetry in spin directions of galaxies

Research also suggests the early universe could have been spinning

An analysis of more than 200,000 spiral galaxies has revealed unexpected links between spin directions of galaxies, and the structure formed by these links...

Im Focus: New measurement exacerbates old problem

Two prominent X-ray emission lines of highly charged iron have puzzled astrophysicists for decades: their measured and calculated brightness ratios always disagree. This hinders good determinations of plasma temperatures and densities. New, careful high-precision measurements, together with top-level calculations now exclude all hitherto proposed explanations for this discrepancy, and thus deepen the problem.

Hot astrophysical plasmas fill the intergalactic space, and brightly shine in stellar coronae, active galactic nuclei, and supernova remnants. They contain...

Im Focus: Biotechnology: Triggered by light, a novel way to switch on an enzyme

In living cells, enzymes drive biochemical metabolic processes enabling reactions to take place efficiently. It is this very ability which allows them to be used as catalysts in biotechnology, for example to create chemical products such as pharmaceutics. Researchers now identified an enzyme that, when illuminated with blue light, becomes catalytically active and initiates a reaction that was previously unknown in enzymatics. The study was published in "Nature Communications".

Enzymes: they are the central drivers for biochemical metabolic processes in every living cell, enabling reactions to take place efficiently. It is this very...

Im Focus: New double-contrast technique picks up small tumors on MRI

Early detection of tumors is extremely important in treating cancer. A new technique developed by researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The work is published May 25 in the journal Nature Nanotechnology.

researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Dresden Nexus Conference 2020: Same Time, Virtual Format, Registration Opened

19.05.2020 | Event News

Aachen Machine Tool Colloquium AWK'21 will take place on June 10 and 11, 2021

07.04.2020 | Event News

International Coral Reef Symposium in Bremen Postponed by a Year

06.04.2020 | Event News

 
Latest News

Why developing nerve cells can take a wrong turn

04.06.2020 | Life Sciences

The broken mirror: Can parity violation in molecules finally be measured?

04.06.2020 | Physics and Astronomy

Innocent and highly oxidizing

04.06.2020 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>